JUPITER 4.0 - Risk Factors for Failure of Isolated Medial Patellofemoral Ligament Reconstruction
Launched by HOSPITAL FOR SPECIAL SURGERY, NEW YORK · Mar 12, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The JUPITER 4.0 trial is studying the outcomes of a surgery called medial patellofemoral ligament (MPFL) reconstruction, which is used to treat people who frequently experience knee cap dislocations, a condition known as recurrent patellar instability. Researchers want to find out what factors might lead to further knee problems after this surgery and how well patients feel their knees are functioning one and two years after the operation.
To participate in this study, individuals need to be between 10 and 35 years old and have a history of patellar instability, meaning they have had at least one dislocated kneecap that required medical attention or meets certain other criteria. During the study, participants will fill out surveys about their knee health and activity levels at one and two years post-surgery. This research aims to help doctors better understand how to improve outcomes for patients with knee instability.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 10-35 years old
- • Recurrent patellar instability with at least one episode defined as either (1) a dislocated patella requiring reduction in the emergency department or (2) a convincing history for dislocation, associated with full giving way, and the following physical findings: (a) hemarthrosis or effusion, (b) tenderness along the medial retinaculum, and (c) apprehension when laterally directed force was applied to the patella or (3) MRI-documented dislocation with associated bone bruises
- Exclusion Criteria:
- • Previous ipsilateral knee surgery
- • Obligatory/fixed/habitual patella dislocation or subluxation
- • Unloadable inferior or lateral chondral damage on the patella that would require a tibial tubercle transfer for unloading purposes
- • Pathologic tibiofemoral instability
About Hospital For Special Surgery, New York
The Hospital for Special Surgery (HSS) in New York is a world-renowned institution specializing in orthopedic surgery, rheumatology, and rehabilitation. Recognized for its commitment to advancing medical research and improving patient outcomes, HSS serves as a leading clinical trial sponsor, facilitating innovative studies that explore cutting-edge treatments and therapies. With a team of expert clinicians and researchers, HSS aims to enhance clinical practices through rigorous scientific inquiry, ultimately contributing to the advancement of musculoskeletal health and patient care on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Boston, Massachusetts, United States
New York, New York, United States
Iowa City, Iowa, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Portland, Oregon, United States
Boston, Massachusetts, United States
Chicago, Illinois, United States
Gainesville, Florida, United States
Redwood City, California, United States
New York, New York, United States
Dallas, Texas, United States
New York, New York, United States
Wake Forest, North Carolina, United States
Dublin, Ohio, United States
Patients applied
Trial Officials
Beth Shubin Stein, MD
Principal Investigator
Hospital for Special Surgery, New York
Shital Parikh, MD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported